Increased Risk of Malignancy With Adalimumab Combination Therapy, Compared With Monotherapy, for Crohn's Disease-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Increased Risk of Malignancy With Adalimumab Combination Therapy, Compared With Monotherapy, for Crohn's Disease

Published:2014-04 Issue:4 Volume:146 Page:941-949.e2
ISSN:0016-5085
Container-title:Gastroenterology
language:en
Short-container-title:Gastroenterology

Author:

Osterman Mark T.,Sandborn William J.,Colombel Jean-Frederic,Robinson Anne M.,Lau Winnie,Huang Bidan,Pollack Paul F.,Thakkar Roopal B.,Lewis James D.

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference41 articles.

1. Long-term evolution of disease behavior of Crohn's disease;Cosnes;Inflamm Bowel Dis,2002

2. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery;Cosnes;Gut,2005

3. Time trends in therapies and outcomes for adult inflammatory bowel disease, Northern California;Herrinton;Gastroenterology,2009

4. Infliximab, azathioprine, or combination therapy for Crohn's disease;Colombel;N Engl J Med,2010

5. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial;Lemann;Gastroenterology,2006

Cited by 165 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 6‐Thioguanine nucleotide levels are associated with infliximab but not adalimumab levels in inflammatory bowel disease patients on combination therapy;Internal Medicine Journal;2024-09-05

2. Adverse Event Profiles of Adalimumab in Children: A Disproportionality Analysis;Pharmaceuticals;2024-08-05

3. Biologics in Focus: A Comprehensive Review of Current Biological and Small Molecules Therapies for Crohn’s Disease in the United Arab Emirates (UAE);Gastrointestinal Disorders;2024-07-07

4. AGA Clinical Practice Update on Management of Inflammatory Bowel Disease in Patients With Malignancy: Commentary;Clinical Gastroenterology and Hepatology;2024-07

5. A Population-Based Matched Cohort Study of Digestive System Cancer Incidence and Mortality in Individuals With and Without Inflammatory Bowel Disease;American Journal of Gastroenterology;2024-06-25

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3